Free Trial Information
BioCentury | May 1, 2006
Strategy

Big enough to share

...Astellas: Adage Capital; Apothecary; Brookside; Corriente Biotechnology; Duquesne Capital; Goldman Sachs; Janus; Merlin BioMed; Och-Ziff; Rosewood...
Read More
BioCentury | Feb 21, 2005
Finance

Ebb & Flow

...were Adage Capital; Apothecary; Brookside; Corriente Biotechnology; Duquesne Capital; Goldman Sachs; Janus; Merlin BioMed; Och-Ziff; Rosewood...
Read More
BioCentury | Feb 16, 2005
Financial News

FibroGen raises $100 million

...Adage Capital; Apothecary; Brookside; Corriente Biotechnology; Duquesne Capital; Goldman Sachs; Janus ; Merlin BioMed; Och-Ziff; Rosewood...
Read More
Items per page:
1 - 3 of 3
BioCentury | May 1, 2006
Strategy

Big enough to share

...Astellas: Adage Capital; Apothecary; Brookside; Corriente Biotechnology; Duquesne Capital; Goldman Sachs; Janus; Merlin BioMed; Och-Ziff; Rosewood...
Read More
BioCentury | Feb 21, 2005
Finance

Ebb & Flow

...were Adage Capital; Apothecary; Brookside; Corriente Biotechnology; Duquesne Capital; Goldman Sachs; Janus; Merlin BioMed; Och-Ziff; Rosewood...
Read More
BioCentury | Feb 16, 2005
Financial News

FibroGen raises $100 million

...Adage Capital; Apothecary; Brookside; Corriente Biotechnology; Duquesne Capital; Goldman Sachs; Janus ; Merlin BioMed; Och-Ziff; Rosewood...
Read More
Items per page:
1 - 3 of 3